Deep vein thrombosis is a frequent manifestation of venous thromboembolism in which there is a blood clot blocking a deep vein.
Clinical findings are important to the diagnosis of deep vein thrombosis but are poor predictors of the presence or severity of thrombosis.
Pulmonary embolism is the blockage of the blood vessels in the lungs usually due to blood clots from the veins, especially veins in the legs and pelvis.
Dyspnea, pleuritic chest pain, syncope and tachypnea occur in most cases of pulmonary embolism.
Massive pulmonary embolism has the prime symptom of dyspnea and systemic arterial hypotension that requires pressor support is the predominant sign.
Elderly cancer patients on anticoagulant therapy are at least nine times more likely to die within 7 days after a major bleeding event than after a venous thromboembolism (VTE) recurrence, suggests a study presented at the EHA Congress 2017 in Madrid, Spain.
Celecoxib is preferred over naproxen when added to proton-pump inhibitor (PPI) for preventing recurrent upper gastrointestinal (GI) bleeding in patients at high risk of both GI and cardiovascular (CV) events, who require concomitant aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), according to the CONCERN* study.
The short-term incidence of thromboembolism and major bleeding after cardioversion is similar between nonvitamin K antagonist oral anticoagulants (NOACs) and dose-adjusted vitamin K antagonist (VKA) therapy, a new study reveals.
The risk of recurrent venous thromboembolism (VTE) is low in women with none or one of the four HERDOO2 criteria (hyperpigmentation, oedema or redness in either leg; D-dimer level ≥250 μg/L while using anticoagulants; obesity with body mass index ≥30; or older age, ≥65 years), a new study reports. These patients can safely discontinue anticoagulants after completing short-term treatment following a first unprovoked VTE event.
Extended therapy with rivaroxaban was more effective than aspirin in reducing the risk of recurrent venous thromboembolism (VTE) with no significant increase in bleeding risk, according to data from the EINSTEIN CHOICE* study presented at the ACC.17 Scientific Session in Washington, DC, US.
A new clinical decision rule (CDR) offers clinicians clues on when to stop anticoagulation therapy in women who had a first, unprovoked venous thromboembolism (VTE), data from the REVERSE II* study, reported at the ESC Congress 2016, have shown.
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Recurrent vascular events in embolic stroke of undetermined source may be directly related to history of diabetes mellitus and the Calcification in the Aortic Arch, Age, Multiple Infarction score, a recent study finds.
Cardiovascular (CV) outcomes were similar between the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride in the CAROLINA* study of patients with early type 2 diabetes (T2D) and increased CV risk.